AFT Pharmaceuticals (ASX:AFP) 3-Year EBITDA Growth Rate : 30.10% (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is AFT Pharmaceuticals 3-Year EBITDA Growth Rate?

AFT Pharmaceuticals's EBITDA per Share for the six months ended in Sep. 2024 was A$-0.00.

During the past 12 months, AFT Pharmaceuticals's average EBITDA Per Share Growth Rate was 8.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 30.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of AFT Pharmaceuticals was 46.80% per year. The lowest was -4.40% per year. And the median was 30.10% per year.

Competitive Comparison of AFT Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AFT Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

AFT Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

AFT Pharmaceuticals (ASX:AFP) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

AFT Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

AFT Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (ASX:AFP) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

AFT:New Zealand

Address

129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622

Website

https://www.aftpharm.com

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.

AFT Pharmaceuticals Headlines

No Headlines